vimarsana.com

Latest Breaking News On - Mycrodose therapeutic - Page 1 : vimarsana.com

Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

/PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in.

State of californiaUnited statesSan diegoBritish columbiaResearch advisory boardNova mentis life science corpUnited states drug enforcement agencyEuropean unionUs food drug administrationMentis life scienceMycrodose therapeuticsFragilex syndromeAutism spectrum disorderWill rascanChief executive officerSouthern california

Mycrodose Therapeutics Receives US DEA Schedule I License to Research Four (4) Psychedelic Compounds

San Diego, California (PRWEB) August 20, 2021 Mycrodose Therapeutics is pleased to announce that the company has been approved by the United States Drug

State of californiaUnited statesSan diegoPatrick eckstromFrank kochinkeResearch advisory boardUs food drug administrationUnited states drug enforcement agencyMycrodose therapeutics an advanced drug delivery companyMycrodose therapeuticsAdvanced drug deliveryChief scienceCalifornia attorney generalDrug administrationMycrodose therapeuticSchedulei license

vimarsana © 2020. All Rights Reserved.